ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. The company currently has laboratory-based immunoassays available to measure the active forms of Neutrophil Elastase, Proteinase 3, Cathepsin G and Plasmin. NEATstik®, a rapid test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
A range of other laboratory-based immunoassays and point-of-care tests designed for routine monitoring of chronic diseases are in development. ProAxsis also offers a highly experienced team who can provide clinical trial support services in regard to the specific measurement of active proteases and other inflammatory biomarkers within clinical samples.
ProAxsis offers measurement of a range of active protease biomarkers, including:
Neutrophil Elastase
Plasmin
Tryptase
Pancreatic Elastase
Our experts provide high quality clinical laboratory studies to investigate protease biomarkers of disease, to include activity profiling of samples and target validation.
ProAxsis can also offer a full range of analytical services for the measurement of other inflammatory mediators and differential cell counts, consulting and data management services within:
ProAxsis is able to support the development of bespoke assays for any protease target.
ProAxsis Limited has not received any reviews.
ProAxsis Limited has not received any endorsements.